<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>The incidence of early recurrent venous thromboembolism</dc:title><dc:creator>Eischer,	Lisbeth	(Avtor)
	</dc:creator><dc:creator>Kyrle,	Paul A.	(Avtor)
	</dc:creator><dc:creator>Kaider,	Alexandra	(Avtor)
	</dc:creator><dc:creator>Schmidt,	Anton	(Avtor)
	</dc:creator><dc:creator>Wildner,	Brigitte	(Avtor)
	</dc:creator><dc:creator>Boc,	Anja	(Avtor)
	</dc:creator><dc:subject>anticoagulation</dc:subject><dc:subject>early recurrence</dc:subject><dc:subject>incidence</dc:subject><dc:subject>meta-analysis</dc:subject><dc:subject>venous thromboembolism</dc:subject><dc:description>Background: Patients with venous thromboembolism (VTE) receive anticoagulation for at least 3 months. To evaluate recurrence risk thereafter, some strategies include D-dimer testing after discontinuing anticoagulation, which raises concern about early recurrence. Objectives: To assess the incidence of recurrent VTE within 30 days after stopping anticoagulation. Methods: We conducted a systematic review of EMBASE, CENTRAL, and MEDLINE to identify controlled trials and cohort studies of adult noncancer patients with deep vein thrombosis of the leg and/or pulmonary embolism treated with anticoagulants for ≥3 months. The primary outcome was symptomatic VTE within 30 days. The risk of bias was assessed using a modified version of the Newcastle-Ottawa Scale. Pooled recurrence rates were calculated using fixed random-effects meta-analyses. Results: Of 42 studies, 24 (57%) provided data, encompassing 11,407 patients. Early recurrence occurred in 115 patients (1.01%), with a pooled incidence of 1.04% (95% CI, 0.8%-1.4%). Men had a risk similar to that of women (risk ratio, 1.2; 95% CI, 0.6-2.3; P = .7). Unprovoked VTE was associated with a 2.6-fold increase in risk (95% CI, 1.4-4.6; P &lt; .001) compared with provoked VTE. Patients with deep vein thrombosis at presentation had a similar risk of recurrence compared with those with an incident pulmonary embolism (risk ratio, 0.6; 95% CI: 0.3-1.2; P = .1). Findings regarding age were inconsistent. None of the recurrences was fatal. The overall risk of bias was low. Conclusion: The incidence of early VTE recurrence after stopping anticoagulation is low. Temporarily discontinuing therapy to assess recurrence risk, therefore, appears safe and may aid in guiding treatment duration.</dc:description><dc:date>2026</dc:date><dc:date>2026-03-31 13:10:15</dc:date><dc:type>Neznano</dc:type><dc:identifier>28737</dc:identifier><dc:identifier>UDK: 616.1</dc:identifier><dc:identifier>ISSN pri članku: 2475-0379</dc:identifier><dc:identifier>DOI: 10.1016/j.rpth.2025.103317</dc:identifier><dc:identifier>COBISS_ID: 273221123</dc:identifier><dc:language>sl</dc:language></metadata>
